GentiBio
PrivateLast Round
Series A
Aug 11, 2021
Total Funding Raised
$177M
Company Overview
GentiBio operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in August 2021.
GentiBio is a biotechnology company that develops engineered regulatory T-cell (EngTreg) therapies to restore immune tolerance and treat autoimmune, alloimmune, autoinflammatory, and allergic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GentiBio Comparables
Compare GentiBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Quell Therapeutics | 87% | |
| Sonoma Biotherapeutics | 86% | |
| Mozart Therapeutics | 86% |
For institutional investors. Book with your work email.
GentiBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 11, 2021 | ||||
| Seed | Aug 5, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
GentiBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A, Seed |
| Avidity Partners | Series A |
| OrbiMed | Series A, Seed |
| Matrix Capital Management | Series A |
| JDRF | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 2, 2026
Will present new data on engineered Treg therapy at the PES Annual Meeting.
- Apr 29, 2026
New data on GNTI-122 Treg therapy to be presented at medical conference.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 11, 2026
GentiBio is set to present its Early Clinical Evaluation of GNTI-122 in recent-onset type 1 diabetes at Breakthrough T1D Clinical Research Conference 2026 in Pennsylvania on Oct 11th '26.
For institutional investors. Book with your work email.
GentiBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GentiBio's valuation, stock price, and market status.
Is GentiBio a public or private company?
GentiBio is a private company.
What is the current stock price of GentiBio?
GentiBio is a private company, so its shares have no public market price. Caplight tracks GentiBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GentiBio worth (valuation)?
Valuation information for GentiBio is not publicly available.
Can I buy GentiBio stock?
GentiBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GentiBio's last funding round?
GentiBio's most recent funding round was Series A on August 11, 2021.
Who are the main investors in GentiBio?
Key investors in GentiBio include RA Capital Management, OrbiMed, Matrix Capital Management.
Will GentiBio IPO soon?
No public IPO plans have been announced for GentiBio.
How can I track GentiBio secondary market activity?
Caplight tracks bids, offers, and trades in GentiBio's shares on secondary markets.